Risk-adapted GVHD prophylaxis with post-transplantation cyclophosphamide in adults after related, unrelated, and haploidentical transplantations.

Ivan Sergeevich MoiseevOlga V PirogovaAlexandr L AlyanskiElena V BabenkoTatyana L GindinaElena I DarskayaOlga A SlesarchukTatyana A BykovaAlexei B ChukhlovinDmitrii E PevtcovSergey N BondarenkoBoris V Afanasyev

Published in: European journal of haematology (2018)

The suggested risk-adapted PTCy-based prophylaxis is feasible and is associated with low GVHD incidence and mortality in all types of grafts. The study was registered on clinicaltrials.gov (NCT02294552).

Keyphrases

risk factors
allogeneic hematopoietic stem cell transplantation
low dose
bone marrow
cardiovascular events
stem cells
cell therapy
coronary artery disease
acute lymphoblastic leukemia
acute myeloid leukemia